Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

Technical420 Site Search

Returned 31 result(s).

Numinus Wellness Is One Of The Shining Stars Of The Psychedelic Sector

So far this year, Numinus Wellness Inc. (TSXV: NUMI) (OTC: LKYSF) has been one of the most active psychedelic companies. The mental health care company is working to bring innovative and evidence-based psychedelic-assisted therapies to market and we are closely following the business.  Numinus is comprised of several divisions and…

Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company Lab

 Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today that it has formed a partnership with KGK Science , a leading contract research organization with expertise in natural products, to undertake a new Psilocybin extraction clinical trial. The Phase…

Numinus Wellness Is Taking Strides To Advance Its R&D Business Unit

The psychedelic therapy market is one of the most exciting emerging industries and is a vertical that we have been highly focused on. We expect 2021 to be a transformational year for the psychedelic sector as companies prepare to report Phase 3 clinical trial data. We expect positive phase 3…

Numinus to expand state-of-the-art psychedelics research laboratory

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), is pleased to announce plans to significantly expand its psychedelics research laboratory by late 2021. A 7,500 square-foot expansion will be developed and…

Numinus Wellness Is Making Major Headway On Its MDMA Trials

Last week, Numinus Wellness Inc. (TSXV: NUMI) reported a major development and we want to issue an update on the opportunity following this announcement. The company is focused on creating an ecosystem of health solutions that are centered around the development of evidence-based psychedelic-assisted psychotherapies. Last week, Numinus announced that…

Numinus Wellness Completes Acquisition of Montreal-based Mindspace Wellbeing

Numinus Wellness Inc.  (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), has closed its acquisition of Mindspace Psychology Services Inc. (DBA Mindspace Wellbeing) , a leader and pioneer in psychedelic programming. The purchase agreement…

Psychedelic Clinics Are A Major Vertical That Investors Need To Be Watching

The clinic opportunity is an exciting vertical of the psychedelic industry and is a market that our readers need to be aware of. Last year, the psychedelic clinic market recorded significant advancements, and this is a trend that is expected to continue. We believe the negative mental health effects that…

2 Psychedelic Stocks Thats Are Flying Under The Radar

From the easing of regulations to the reporting of positive clinical trial data, the psychedelic sector is a rapidly evolving industry that is starting to show serious signs of legitimacy. We believe the biggest potential catalyst for the psychedelic sector would be the reporting of positive data from Phase 3…

Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products

Numinus Wellness Inc.  (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), announced today that it has signed a lab services agreement with Optimi Health Corp., developers of a vertically integrated functional mushroom brand focused…

Numinus Wellness Announces National Expansion with Acquisition of Montreal-Based Mindspace Wellbeing, a Full-service Well-being Organization and Pioneer in Psychedelic Programming

Numinus Wellness Inc.  (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), is pleased to announce the acquisition of Montreal -based Mindspace Psychology Services Inc (DBA Mindspace Wellbeing), a leader and pioneer in psychedelic programming.…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link